Imagine a tiny, smart pacemaker for the brain that doesn't require deep surgery. It sits on the surface of the skull and sends precise electrical pulses to calm down overactive brain areas. This helps stop seizures in people who don't respond to traditional medication.
Drug-refractory epilepsy creates a massive economic burden of 20 bn Euros annually. Current surgical options are often too invasive, leaving a gap for a minimally invasive, effective stimulation therapy.
The EASEE system, a minimally invasive epicranial stimulation device with a redesigned PCBA for lower power consumption and automated manufacturing processes.
If you are a hardware producer dealing with high power consumption in implants — this project developed a redesigned PCBA and HW/SW codesign that significantly lowers energy use. This extends the device lifetime and improves patient safety.
If you are a clinic dealing with the 6 million epilepsy patients in Europe who are drug-refractory — this project developed the EASEE system. It provides a minimally invasive alternative to deep brain surgery to reduce seizure frequency.
If you are a payer dealing with the 20 bn Euros annual healthcare costs for epilepsy — this project developed a scalable series product for market entry. Reducing the burden of drug-refractory cases can lower long-term care expenses.
Based on available project data, specific unit pricing or cost per device is not mentioned; however, the project focuses on reducing the 20 bn Euro annual healthcare burden of epilepsy.
The project developed a process to transfer manual prototype manufacturing to controlled, scalable, and partly automated production steps.
One of the main objectives of the project was to improve IPR operability to secure the business case for market entry.
Yes, all design activities were aligned to be compatible with the new Medical Device Regulation (MDR) compliance requirements.
The project ran from March 2023 to February 2025, aiming to move the system from TRL 6-7 to TRL 9 for series production.
The project is led by a single SME, Precisis GmbH from Germany, which represents 100% of the industry ratio. This lean structure indicates a highly focused commercialization effort, moving a proprietary technology directly from a clinical prototype to a market-ready product without the overhead of academic partners.
Contact Precisis GmbH regarding the EASEE system commercial licensing.
Contact us to explore partnership opportunities with Precisis GmbH for neuromodulation deployment.
